Citigroup Maintains Buy on Mirum Pharmaceuticals, Raises Price Target to $184

Citigroup analyst Yigal Nochomovitz has maintained a Buy rating on Mirum Pharmaceuticals (NASDAQ: MIRM) and increased the price target from $160 to $184. This adjustment reflects positive expectations for the company's performance in the market.